Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06770855 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Jun 30, 2026 to Jun 12, 2026 · Eligibility criteria expanded, about 10 words · Site details revised Show 3 more changesShow less
    • Start date changed from estimate of Jun 30, 2026 to Jun 12, 2026
    • Eligibility criteria expanded, about 10 words
    • Site details revised
  2. Start date: Apr 11, 2026 to Jun 30, 2026v5
  3. Start date: Nov 11, 2025 to Apr 11, 2026v4
  4. Phase: Phase 2 to Not applicable Start date: Jul 2025 to Nov 11, 2025v3 Show 1 more changeShow less
    • Start date: Jul 2025 to Nov 11, 2025
  5. Start date: Jan 2025 to Jul 2025 Enrollment target: 20 to 23 · Primary and study completion dates: Mar 2028 to Sep 2028v2 Show 2 more changesShow less
    • Enrollment target: 20 to 23
    • Primary and study completion dates: Mar 2028 to Sep 2028
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial response/stable disease after at least 6 months of immune checkpoint blockade-based therapy for metastatic clear cell RCC. The investigators hypothesize that patients who undergo total consolidative MPDT followed by systemic therapy discontinuation will have a 12-month treatment-free survival rate of 32% compared to a null hypothesis of 13%
Trial Details
NCT Number NCT06770855
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Renal Cell Carcinoma
Enrollment 23 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov